Neoadjuvant Pembrolizumab: 71% Response Rate in Resectable Desmoplastic Melanoma

A new study offers promising results for the treatment of desmoplastic melanoma, a rare and aggressive form of skin cancer. Researchers have found that neoadjuvant pembrolizumab, an immunotherapy drug, achieved a significant pathological complete response rate in patients with surgically resectable disease.

What is Desmoplastic Melanoma?

Desmoplastic melanoma is a less common subtype of melanoma, accounting for a small percentage of all melanoma diagnoses. It often presents differently than more typical melanomas, frequently lacking the pigment that gives many skin cancers their color. This can make it more difficult to detect. It typically arises on sun-exposed areas and is characterized by spindle-shaped cells within a dense collagenous stroma, often accompanied by collections of immune cells.

The SWOG S1512 Trial: A Detailed Look

The findings come from cohort A of the phase 2 SWOG S1512 trial (January 29, 2026 publication date), designed to evaluate the effectiveness of pembrolizumab – an anti-programmed cell death protein 1 (anti-PD-1) therapy – in individuals with desmoplastic melanoma. The trial involved 28 patients with resectable desmoplastic melanoma who received intravenous pembrolizumab at a dose of 200 mg every three weeks for three cycles before undergoing surgical removal of the tumor.

Researchers meticulously reviewed tissue samples collected before treatment, during treatment (3-5 weeks after initiation) and at the time of surgery. This allowed for a comprehensive assessment of the drug’s impact on the tumor. Beyond the primary endpoint of pathological complete response, the study also tracked clinical response rate, overall survival, and any treatment-related toxicities.

Impressive Pathological Complete Response Rate

The primary endpoint of the study – the pathological complete response (pCR) rate – was a remarkable 71% (95% confidence interval: 51-87%; P < 0.001). This means that in over two-thirds of the patients, no evidence of cancer remained in the surgically removed tissue after treatment with neoadjuvant pembrolizumab. This result significantly exceeded expectations and suggests a substantial benefit from this approach.

Long-Term Outcomes and Safety Profile

Follow-up data extending to three years revealed that four participants had died during the study period. Importantly, none of these deaths were attributed to melanoma or related to adverse events from the treatment. This is encouraging and suggests a favorable long-term safety profile.

The treatment was generally well-tolerated, with only two patients (7%) experiencing grade 3 treatment-related adverse events. This indicates that the side effects were manageable and did not significantly compromise patient well-being. The absence of additional high-grade toxicities further supports the drug’s acceptable safety profile.

What Does This Mean for Patients?

These findings represent a significant step forward in the treatment of desmoplastic melanoma. Neoadjuvant pembrolizumab, meaning the drug is given before surgery, appears to be a highly effective strategy for shrinking tumors and potentially improving long-term outcomes. The high pCR rate suggests that this approach could lead to more successful surgical resections and potentially reduce the risk of recurrence.

The study authors concluded that neoadjuvant pembrolizumab in patients with resectable desmoplastic melanoma results in a high pCR rate with an acceptable safety profile. The data support further investigation of neoadjuvant programmed cell death protein 1 blockade in this specific melanoma subtype.

Looking Ahead

While these results are promising, it’s important to remember that this was a phase 2 trial. Larger, randomized phase 3 trials are needed to confirm these findings and establish pembrolizumab as a standard of care for desmoplastic melanoma. Further research will also focus on identifying biomarkers that can predict which patients are most likely to benefit from this treatment approach. The ongoing evaluation of overall survival will also provide crucial insights into the long-term impact of neoadjuvant pembrolizumab.

This research highlights the growing role of immunotherapy in cancer treatment and offers hope for improved outcomes for patients with this challenging form of melanoma.

Reference

Kendra KL et al. Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial. Nat Cancer. 2026;https://doi.org/10.1038/s43018-025-01113-y.